New CFO recruited to aid new spurt of growth for Domainex
Domainex, a private Cambridge drug discovery services company, has unveiled Chris Brown as chief financial officer.
The company said he would have a pivotal role in supporting the organisation through ongoing and significant growth and investment; his appointment will strengthen both the existing board and executive management team.
Domainex is expanding rapidly, with compounded annual growth in revenue of over 30 per cent per annum during the past five years and an increase in its international team of scientists at the company’s research facilities on the Chesterford Research Park of more than 50 per cent in the past 12 months.
Brown (pictured above) said: “I am thrilled to join Domainex at this exciting stage of the company’s development. Domainex enjoys an outstanding reputation for scientific excellence in drug discovery.
“I believe we are in a strong position to build on our capabilities to serve our global client base and look forward to developing and implementing our future growth strategies in drug discovery services.”
Brown is a mathematics graduate of Imperial College and a chartered accountant. He has extensive experience within the life sciences industry with over 10 years at Envigo where he rose to become senior vice-president of finance.
He brings a strong financial technical skill set to the company and experience in M & A transactions having previously acted as the financial lead on the acquisition of Harlan Laboratories, a 2,000-person global scientific models and CRO business, to create Envigo.
Domainex executive chairman Dr Timo Veromaa said: “We are exploring a number of exciting growth opportunities for Domainex and feel Chris’ expertise will be of tremendous value in this area.”
Brown replaces Barry Knight who has moved on to a fresh challenge.